BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 9437229)

  • 1. The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations.
    Arvat E; Ramunni J; Bellone J; Di Vito L; Baffoni C; Broglio F; Deghenghi R; Bartolotta E; Ghigo E
    Eur J Endocrinol; 1997 Dec; 137(6):635-42. PubMed ID: 9437229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
    Arvat E; di Vito L; Maccagno B; Broglio F; Boghen MF; Deghenghi R; Camanni F; Ghigo E
    Peptides; 1997; 18(6):885-91. PubMed ID: 9285939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans.
    Arvat E; Maccagno B; Ramunni J; Di Vito L; Broglio F; Deghenghi R; Camanni F; Ghigo E
    Neuroendocrinology; 1997 Dec; 66(6):432-8. PubMed ID: 9430449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.
    Ghigo E; Arvat E; Ramunni J; Colao A; Gianotti L; Deghenghi R; Lombardi G; Camanni F
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
    Arvat E; Maccagno B; Ramunni J; Gianotti L; Di Vito L; Deghenghi R; Camanni F; Ghigo E
    J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dexamethasone and alprazolam, a benzodiazepine, on the stimulatory effect of hexarelin, a synthetic GHRP, on ACTH, cortisol and GH secretion in humans.
    Arvat E; Maccagno B; Ramunni J; Di Vito L; Gianotti L; Broglio F; Benso A; Deghenghi R; Camanni F; Ghigo E
    Neuroendocrinology; 1998 May; 67(5):310-6. PubMed ID: 9641612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of galanin and serotonin on the endocrine response to Hexarelin, a synthetic peptidyl GH-secretagogue, in normal women.
    Arvat E; Maccagno B; Ramunni J; Broglio F; Lanfranco F; Giordano R; Benso A; Deghenghi R; Ghigo E
    J Endocrinol Invest; 1998 Nov; 21(10):673-9. PubMed ID: 9854683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.
    Bellone J; Bartolotta E; Sgattoni C; Aimaretti G; Arvat E; Bellone S; Deghenghi R; Ghigo E
    J Endocrinol Invest; 1998 Sep; 21(8):494-500. PubMed ID: 9801989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.
    Arvat E; Di Vito L; Lanfranco F; Broglio F; Giordano R; Benso A; Muccioli GP; Deghenghi R; Ghigo E
    J Endocrinol Invest; 1999 Feb; 22(2):91-7. PubMed ID: 10195374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging.
    Arvat E; Ceda GP; Di Vito L; Ramunni J; Gianotti L; Broglio F; Deghenghi R; Ghigo E
    Pituitary; 1998 Apr; 1(1):51-8. PubMed ID: 11081183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing's disease.
    Arvat E; Ramunni J; Giordano R; Maccagno B; Broglio F; Benso A; Deghenghi R; Ghigo E
    J Endocrinol Invest; 1999 Jan; 22(1):23-8. PubMed ID: 10090133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison's disease.
    Arvat E; Ramunni J; Maccagno B; Giordano R; Broglio F; Deghenghi R; Boscaro M; Ghigo E
    Neuroendocrinology; 1999 Sep; 70(3):200-6. PubMed ID: 10516483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oestrogen replacement does not restore the reduced GH-releasing activity of Hexarelin, a synthetic hexapeptide, in post-menopausal women.
    Arvat E; Gianotti L; Broglio F; Maccagno B; Bertagna A; Deghenghi R; Camanni F; Ghigo E
    Eur J Endocrinol; 1997 May; 136(5):483-7. PubMed ID: 9186268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease.
    Grottoli S; Arvat E; Gauna C; Maccagno B; Ramunni J; Giordano R; Maccario M; Deghenghi R; Ghigo E
    Pituitary; 1999 Nov; 2(3):197-204. PubMed ID: 11081154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging.
    Ghigo E; Arvat E; Gianotti L; Grottoli S; Rizzi G; Ceda GP; Boghen MF; Deghenghi R; Camanni F
    Eur J Endocrinol; 1996 Oct; 135(4):407-12. PubMed ID: 8921821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans.
    Arvat E; Maccagno B; Ramunni J; Giordano R; Broglio F; Gianotti L; Maccario M; Camanni F; Ghigo E
    Eur J Endocrinol; 2000 Nov; 143(5):601-6. PubMed ID: 11078983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.
    Maccario M; Veldhuis JD; Broglio F; Vito LD; Arvat E; Deghenghi R; Ghigo E
    Eur J Endocrinol; 2002 Mar; 146(3):310-8. PubMed ID: 11888836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine activities of alexamorelin (Ala-His-d-2-methyl-Trp-Ala-Trp-d-Phe-Lys-NH2), a synthetic GH secretagogue, in humans.
    Broglio F; Benso A; Gottero C; Muccioli G; Deghenghi R; Ghigo E; Arvat E
    Eur J Endocrinol; 2000 Sep; 143(3):419-25. PubMed ID: 11022186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.